Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue…

]]>
Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of Health. Initial Order Sufficient to Treat 500 Patients. Positive Interim Safety and Symptoms Improvement Observed in…

]]>
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply Agreement Kamada…

]]>
The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyper-immune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with Pneumonia Symptoms Improvement Observed in 11 of the 12…

]]>